Liquidia Corporation Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Liquidia Corporation (NASDAQ: LQDA) announced the grant of inducement stock options for 10,000 shares to newly hired non-executive employees under its Inducement Plan. Each option, intended as part of the employment compensation, is exercisable at $6.39 per share, the closing price on the grant date of February 1, 2023. The options have a ten-year term and vest over four years, with 25% vesting on the first anniversary and the remainder vesting monthly thereafter. The Inducement Plan specifically allows for non-statutory stock options for individuals who are new hires or returning after a period of non-employment.
- Grant of inducement stock options could attract talent, potentially enhancing company performance.
- Stock options exercisable at $6.39 align with recent closing price, indicating potential for value appreciation.
- None.
MORRISVILLE, N.C., Feb. 02, 2023 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) today announced the grant of inducement stock options exercisable for an aggregate of 10,000 shares of Liquidia’s common stock to newly hired non-executive employees under the Liquidia Corporation 2022 Inducement Plan (the “Inducement Plan”). Each stock option was granted as an inducement material to the grantee’s acceptance of employment with Liquidia (or one of its subsidiaries) as a component of the grantee’s employment compensation in accordance with Nasdaq Listing Rule 5635(c)(4).
The Inducement Plan is used exclusively for the grant of non-statutory stock option awards to individuals who were not previously employees of Liquidia (or following a bona fide period of non-employment), as an inducement material to such individual’s entering into employment with Liquidia, pursuant to Rule 5635(c)(4) of the Nasdaq Listing Rules.
Each stock option is exercisable at a price of
About Liquidia Corporation
Liquidia Corporation is a biopharmaceutical company focused on the development and commercialization of products in pulmonary hypertension and other applications of its PRINT® Technology. The company operates through its two wholly owned subsidiaries, Liquidia Technologies, Inc. and Liquidia PAH, LLC. Liquidia Technologies has developed YUTREPIA™ (treprostinil) inhalation powder for the treatment of pulmonary arterial hypertension (PAH). Liquidia PAH provides the commercialization for rare disease pharmaceutical products, such as generic Treprostinil Injection. For more information, please visit www.liquidia.com.
Contact Information
Media & Investors:
Jason Adair
Senior Vice President, Corporate Development and Strategy
919.328.4400
jason.adair@liquidia.com
FAQ
What is the recent stock option grant by Liquidia Corporation?
What is the exercise price for the new stock options at Liquidia Corporation?
When were the stock options granted by Liquidia Corporation?
How long do the stock options at Liquidia Corporation last?